Garenoxacin is a broad-spectrum antibiotic belonging to the fluoroquinolone class, primarily developed for the treatment of bacterial infections. It demonstrates strong activity against a wide range of Gram-positive and Gram-negative pathogens, including those resistant to other antibiotics. It has been used in the management of respiratory tract infections such as pneumonia and bronchitis, especially where atypical bacteria like *Mycoplasma pneumoniae* or *Chlamydophila pneumoniae* are involved. It also shows efficacy in treating urinary tract infections and skin and soft tissue infections. Due to its favorable pharmacokinetic profile, garenoxacin achieves high concentrations in tissues and maintains prolonged antibacterial action, allowing for once-daily dosing. Although development and marketing have been limited in some regions, it remains a valuable option in certain resistant infection cases where alternative fluoroquinolones may be less effective.